$GNFT News
Last published 3y ago
- 3y agoGNFTSeal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)PR NewswireSeal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a
- 4y agoBLRXEPAYGNFTOBSV+1Thinking about buying stock in Spruce Biosciences, Bottomline Technologies, BioLine RX, Obseva SA, or Genfit SA?PR NewswireNEW YORK, Dec. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPRB, EPAY, BLRX, OBSV, and GNFT.
- 4y agoGNFTIPSEYIpsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global PartnershipBusiness WireAgreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global
- 6y agoGNFTGENFIT SA (GNFT) CEO Pascal Prigent on Q2 2020 Results - Earnings Call TranscriptEarnings Call Transcripts
- 6y agoGNFTPhase 3 Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) - NCT04526665ClinicalTrials.govEffect of elafibranor (80 mg/day) on cholestasis, Response to treatment based on ALP normalization, Change in pruritis from baseline
- 6y agoGNFTGENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASHGlobeNewswireGENFIT: Positive 42-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT...
- 7y agoGNFTTerns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China RegionBusiness WireFOSTER CITY, Calif. & SHANGHAI--(BUSINESS WIRE)--Terns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases. Under the terms of the agreement, Terns acquires the exclusive ...